{
  "id": "bernard-soulier-syndrome",
  "title": "Bernard–Soulier syndrome",
  "lang": "en",
  "source_lang": "en",
  "summary": "Bernard–Soulier syndrome is a rare inherited bleeding disorder characterized by defective platelet adhesion, unusually large platelets, and a reduced platelet count.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "Bernard–Soulier disease",
    "Hemorrhagiparous thrombocytic dystrophy",
    "Giant platelet syndrome"
  ],
  "generated_at": "2026-11-04",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/bernard-soulier-syndrome/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/bernard-soulier-syndrome/",
      "json": "https://aiwiki.page/zh/bernard-soulier-syndrome.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Bernard–Soulier syndrome (BSS) is a rare inherited bleeding disorder caused by deficiency or dysfunction of the platelet glycoprotein Ib–IX–V receptor complex. This complex normally helps platelets attach to injured blood vessels by binding von Willebrand factor. The classic disorder combines impaired platelet adhesion with unusually large platelets and a reduced platelet count, a combination called macrothrombocytopenia. Bleeding most often affects the skin and mucous membranes, although severe hemorrhage can occur."
    },
    {
      "heading": "Biological basis",
      "text": "Platelets are small blood-cell fragments involved in forming the initial plug at a site of vascular injury. The glycoprotein Ib–IX–V complex on their surface captures von Willebrand factor attached to the injured vessel wall, particularly under conditions of rapid blood flow. This interaction initiates platelet adhesion and supports subsequent platelet activation and plug formation.\n\nIn Bernard–Soulier syndrome, the receptor complex is absent, reduced, or functionally abnormal. Platelets therefore attach less effectively to damaged vessels. Abnormal platelet production and size regulation also contribute to the characteristic giant platelets and low platelet count, or thrombocytopenia. Bleeding reflects both the functional defect and the reduced number of circulating platelets.\n\nThis is primarily a disorder of platelet-mediated hemostasis rather than a deficiency of plasma coagulation factors, as occurs in hemophilia."
    },
    {
      "heading": "Genetics and inheritance",
      "text": "Classic Bernard–Soulier syndrome usually results from pathogenic variants in both copies of one of three genes: GP1BA, GP1BB, or GP9. These encode the GPIbα, GPIbβ, and GPIX components of the receptor complex, respectively.\n\nThe classic form follows autosomal recessive inheritance. When both parents carry a pathogenic variant in the same relevant gene, each pregnancy has a 25% probability of producing an affected child, a 50% probability of producing a carrier, and a 25% probability of producing a child who inherited neither variant.\n\nCertain single-copy variants, particularly in GP1BA or GP1BB, can cause dominantly inherited macrothrombocytopenia, sometimes termed monoallelic Bernard–Soulier syndrome. These forms are generally milder than classic biallelic disease. Not every variant in these genes causes the same disorder; some GP1BA variants instead cause platelet-type von Willebrand disease through increased, rather than reduced, binding to von Willebrand factor."
    },
    {
      "heading": "Clinical features",
      "text": "Classic disease often becomes apparent during childhood. Common manifestations include:\n\n- Easy bruising and prolonged bleeding from minor injuries.\n- Recurrent nosebleeds and bleeding from the gums.\n- Heavy menstrual bleeding.\n- Excessive bleeding after dental procedures, surgery, or childbirth.\n\nRepeated blood loss can cause iron-deficiency anemia. Gastrointestinal bleeding and other serious hemorrhages can occur, but bleeding severity varies substantially. The platelet count alone does not reliably predict an individual’s bleeding tendency."
    },
    {
      "heading": "Diagnosis",
      "text": "Diagnosis combines the bleeding and family history with blood-cell examination, platelet function testing, and, where appropriate, molecular genetic testing.\n\nA complete blood count commonly shows thrombocytopenia. Examination of a peripheral blood smear identifies large or giant platelets. Automated analyzers may fail to recognize some giant platelets and consequently underestimate the platelet count.\n\nCharacteristic laboratory findings include:\n\n- Impaired ristocetin-induced platelet agglutination. Ristocetin normally promotes binding between von Willebrand factor and GPIb. This response is markedly reduced or absent in classic BSS.\n- Failure of normal plasma to correct the ristocetin response. The defect lies in the platelet receptor, not simply in a missing plasma protein.\n- Reduced receptor expression. Flow cytometry commonly demonstrates reduced or absent platelet GPIb–IX expression, assessed using markers such as CD42b and CD42a. Some functional variants retain substantial receptor expression.\n- Usually normal routine coagulation times. Prothrombin time and activated partial thromboplastin time are generally normal unless another condition is present.\n\nResponses to other platelet agonists are often relatively preserved, although testing is complicated by low platelet counts and abnormal platelet size. Identification of causative genetic variants can confirm the diagnosis and clarify inheritance.\n\nImportant conditions in the differential diagnosis include immune thrombocytopenia, other inherited macrothrombocytopenias, von Willebrand disease, and platelet-type von Willebrand disease. Misclassification as immune thrombocytopenia can lead to treatments that do not address the inherited receptor defect."
    },
    {
      "heading": "Management and clinical course",
      "text": "Management is directed at controlling bleeding and providing hemostatic support during procedures or childbirth. Established approaches include local hemostatic measures and antifibrinolytic medicines, such as tranexamic acid, particularly for mucosal bleeding.\n\nPlatelet transfusion is used for severe bleeding or major procedures. Repeated exposure can produce antibodies against donor antigens, including the missing platelet receptor, potentially reducing the effectiveness of later transfusions. Recombinant activated factor VII has been used in selected difficult-to-treat cases, but evidence in BSS is limited.\n\nHematopoietic stem cell transplantation has corrected the disorder in a small number of severely affected patients; its risks limit its use. Genetic counseling addresses inheritance and family testing.\n\nThe disorder is lifelong, but its clinical burden varies. Significant risks arise during major hemostatic challenges, including surgery and childbirth. Evidence about long-term outcomes and less common treatments is constrained by the rarity of the condition."
    },
    {
      "heading": "History",
      "text": "French physicians Jean Bernard and Jean-Pierre Soulier first described the disorder in 1948. Subsequent studies identified the platelet adhesion defect and established the central role of the GPIb–IX–V receptor complex in normal hemostasis."
    }
  ],
  "links": [
    "platelet",
    "hemophilia",
    "gene",
    "autosomal-recessive-inheritance",
    "surgery",
    "iron-deficiency-anemia",
    "diagnosis",
    "complete-blood-count",
    "flow-cytometry",
    "differential-diagnosis",
    "blood-transfusion",
    "hematopoietic-stem-cell-transplantation"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}